MorphoSys AG (ETR:MOR) has been assigned a €59.00 ($69.41) target price by equities researchers at HSBC Holdings plc in a research note issued on Friday, July 14th. The brokerage presently has a “neutral” rating on the stock.

MOR has been the subject of several other reports. Independent Research GmbH set a €77.00 ($90.59) price objective on MorphoSys AG and gave the company a “buy” rating in a report on Monday, May 29th. Berenberg Bank set a €68.00 ($80.00) target price on MorphoSys AG and gave the company a “buy” rating in a report on Thursday, May 25th. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the company a “buy” rating in a report on Tuesday, May 30th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on MorphoSys AG and gave the company a “neutral” rating in a report on Tuesday, June 6th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. MorphoSys AG has an average rating of “Buy” and an average target price of €69.57 ($81.85).

Shares of MorphoSys AG (ETR MOR) traded up 1.000% during mid-day trading on Friday, hitting €59.809. The company had a trading volume of 1,619 shares. MorphoSys AG has a 52-week low of €35.72 and a 52-week high of €70.90. The stock’s 50-day moving average is €62.66 and its 200-day moving average is €57.52. The stock’s market cap is €1.72 billion.

COPYRIGHT VIOLATION WARNING: “HSBC Holdings plc Reiterates “€59.00” Price Target for MorphoSys AG (ETR:MOR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/08/morphosys-ag-etrmor-pt-set-at-59-00-by-hsbc-holdings-plc-updated-updated-updated.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.